Literature DB >> 19238676

K-ras mutations and cetuximab in colorectal cancer.

Wendy De Roock, Diether Lambrechts, Sabine Tejpar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19238676

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

1.  Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.

Authors:  Humaid O Al-Shamsi; Jeremy Jones; Yazan Fahmawi; Ibrahim Dahbour; Aziz Tabash; Reham Abdel-Wahab; Ahmed O S Abousamra; Kenna R Shaw; Lianchun Xiao; Manal M Hassan; Benjamin R Kipp; Scott Kopetz; Amr S Soliman; Robert R McWilliams; Robert A Wolff
Journal:  J Gastrointest Oncol       Date:  2016-12

2.  KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications.

Authors:  Katharina Balschun; Jochen Haag; Ann-Kathrin Wenke; Witigo von Schönfels; Nicolas T Schwarz; Christoph Röcken
Journal:  J Mol Diagn       Date:  2011-05-04       Impact factor: 5.568

Review 3.  Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review.

Authors:  Jara M Baas; Lisanne L Krens; Henk-Jan Guchelaar; Hans Morreau; Hans Gelderblom
Journal:  Oncologist       Date:  2011-07-08

4.  Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.

Authors:  Christina Wu; Terence M Williams; Evan Wuthrick; Ryan Robb; Amy Webb; Lai Wei; Wei Chen; Sameh Mikhail; Kristen K Ciombor; Dana B Cardin; Cynthia Timmers; Somashekar G Krishna; Mark Arnold; Alan Harzman; Sherif Abdel-Misih; Sameek Roychowdhury; Tanios Bekaii-Saab
Journal:  Clin Cancer Res       Date:  2020-04-06       Impact factor: 12.531

Review 5.  Predictive and prognostic markers in colorectal cancer.

Authors:  Ben George; Scott Kopetz
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

6.  Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.

Authors:  Hiroshi Soeda; Hideki Shimodaira; Mika Watanabe; Takao Suzuki; Makio Gamoh; Takahiro Mori; Keigo Komine; Noriyuki Iwama; Shunsuke Kato; Chikashi Ishioka
Journal:  Int J Clin Oncol       Date:  2012-05-26       Impact factor: 3.402

7.  Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer.

Authors:  Fotios Loupakis; Chiara Cremolini; Gabriella Fontanini; Irene Stasi; Lisa Salvatore; Alfredo Falcone
Journal:  Ther Adv Med Oncol       Date:  2009-11       Impact factor: 8.168

8.  Accomplishments in 2008 in biologic markers for gastrointestinal cancers-focus on colorectal cancer.

Authors:  Sabine Tejpar; Robert D Odze
Journal:  Gastrointest Cancer Res       Date:  2009-09

Review 9.  Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

Authors:  Nicola Normanno; Sabine Tejpar; Floriana Morgillo; Antonella De Luca; Eric Van Cutsem; Fortunato Ciardiello
Journal:  Nat Rev Clin Oncol       Date:  2009-07-28       Impact factor: 66.675

10.  Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan.

Authors:  Seung Tae Kim; Tae Jin Ahn; Eunjin Lee; In-Gu Do; Su Jin Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Suk Hyeong Kim; Jeeyun Lee; Hee Cheol Kim
Journal:  BMC Cancer       Date:  2015-10-20       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.